Any current/future new fundraising through debt or equity?

No specific mention of current or future fundraising through debt or equity was disclosed in the transcript. The company discussed ongoing and planned capital expenditures, including ₹1,000 crores assumed for the current year, mainly towards the Kakinada Greenfield project and other expansions. Management stated CAPEX is ongoing and will be based on project finalizations but did not indicate any planned fundraising. Cash on hand was reported at ₹3,602 crores as of September 30, 2024, indicating strong liquidity. Any substantial future CAPEX requiring additional funding would be communicated as

Any current/future capex/capital investment/strategic investment?

Divi’s Laboratories is undertaking a significant Greenfield expansion at Unit-III, a 200-acre project. Phase-wise production at Unit-III is expected to commence from December 2024. Capital work-in-progress as of September 30, 2024, stands at ₹1,316 crores, with the Kakinada project accounting for ₹1,006 crores. Total amount spent on the Kakinada project till September 30, 2024 is ₹1,181 crores. Capitalized assets during the current quarter were ₹64 crores and ₹124 crores during the half year. The company anticipates CAPEX of approximately ₹1,000 crores including Kakinada for the current year,

Future growth expectations in sales/revenue/volumes?

Existing generic products are stable with volume growth. Sartan business is growing steadily. Future generics launching from 2026 to 2029, currently in customer qualification phases, expected to contribute significantly. Custom synthesis projects focused on GLP-1 peptides show huge opportunities, with many molecules in phase II/III trials. Contrast media volumes expected to grow 20-30% year-on-year. Increased number of RFPs and onsite customer visits indicate growing demand in custom synthesis. Advanced shipments and extended supply chain measures support volume growth despite logistical chall

Future growth expectations in earnings/operating earnings/profits/EPS?

Divi’s Laboratories expects revenue growth driven by six growth engines including stable existing generics, steadily growing Sartan business, and launch of future generics from 2026 through 2029. New generics currently in various qualification stages are expected to start contributing revenues from 2026 onward. Custom synthesis, especially in GLP-1 peptides and other phase II/III molecules, shows strong demand and opportunities. Contrast media segment and expansion in solid phase peptide synthesis capacities are projected to support volume and revenue growth. Greenfield expansion at Unit-III s

Current/ Expected Orderbook/ Pending Orders?

Divi’s Laboratories receives numerous RFQs (Requests for Quotations) from customers at various stages: phase-I, phase-II, phase-III, or ready to launch. Conversion of RFQs into business depends on the molecule's development stage, regulatory approvals, and customer strategy. The timeline for converting RFQs to business varies widely; some projects may move slowly due to regulatory or development issues. There is a ₹650 to ₹700 crore dedicated project expected to become an opportunity by FY'27, but details remain confidential. The company is actively qualifying products for future generic suppl

Divi's Lab.Q2 FY25Pharmaceuticals & Biotechnology

Divi's Lab. Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹9,664P/E: 86.1Market Cap: ₹2.6L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Existing generic products are stable with volume growth.
Sartan business is growing steadily.
Future generics launching from 2026 to 2029, currently in customer qualification phases, expected to contribute significantly.
Custom synthesis projects focused on GLP-1 peptides show huge opportunities, with many molecules in phase II/III trials.
Contrast media volumes expected to grow 20-30% year-on-year.
Increased number of RFPs and onsite customer visits indicate growing demand in custom synthesis.
Advanced shipments and extended supply chain measures support volume growth despite logistical challenges.
Volume-based growth in generic products is double-digit, contributing to 49% of total revenue.
Unit-III expansion (starting December 2024) will support volume ramp-up over time.
Pricing pressure in generics expected to stabilize within 6-12 months, supporting revenue growth.

Margin guidance

Category 3

Divi’s Laboratories expects revenue growth driven by six growth engines including stable existing generics, steadily growing Sartan business, and launch of future generics from 2026 through 2029.
New generics currently in various qualification stages are expected to start contributing revenues from 2026 onward.
Custom synthesis, especially in GLP-1 peptides and other phase II/III molecules, shows strong demand and opportunities.
Contrast media segment and expansion in solid phase peptide synthesis capacities are projected to support volume and revenue growth.
Greenfield expansion at Unit-III starting production from December 2024 will add capacity; EBITDA breakeven is expected to be gradual as commercial supplies stabilize.
Despite generic pricing pressure, volume growth and market share gains in generics support earnings.
The company anticipates margin normalization and sustainable double-digit growth over full fiscal years.
CAPEX remains high (~₹1,600 crores current year), reflecting investments for future growth, with further additions aligned to new projects and expansions.

See what Divi's Lab. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No specific mention of current or future fundraising through debt or equity was disclosed in the transcript.
The company discussed ongoing and planned capital expenditures, including ₹1,000 crores assumed for the current year, mainly towards the Kakinada Greenfield project and other expansions.
Management stated CAPEX is ongoing and will be based on project finalizations but did not indicate any planned fundraising.
Cash on hand was reported at ₹3,602 crores as of September 30, 2024, indicating strong liquidity.
Any substantial future CAPEX requiring additional funding would be communicated as needed.
No direct references were made regarding plans for raising funds via debt or equity during this earnings call.

Order book

Divi’s Laboratories receives numerous RFQs (Requests for Quotations) from customers at various stages: phase-I, phase-II, phase-III, or ready to launch.
Conversion of RFQs into business depends on the molecule's development stage, regulatory approvals, and customer strategy.
The timeline for converting RFQs to business varies widely; some projects may move slowly due to regulatory or development issues.
There is a ₹650 to ₹700 crore dedicated project expected to become an opportunity by FY'27, but details remain confidential.
The company is actively qualifying products for future generic supply starting mostly from 2026 onwards.
Expansion and investment decisions continue based on finalized custom synthesis projects and customer demand.
Overall, the order pipeline is strong but subject to confidentiality and regulatory factors, making precise quantification difficult.

See what Divi's Lab. management said on order book — free account, 30 seconds.

Capex plans

Yes

Divi’s Laboratories is undertaking a significant Greenfield expansion at Unit-III, a 200-acre project.
Phase-wise production at Unit-III is expected to commence from December 2024.
Capital work-in-progress as of September 30, 2024, stands at ₹1,316 crores, with the Kakinada project accounting for ₹1,006 crores.
Total amount spent on the Kakinada project till September 30, 2024 is ₹1,181 crores.
Capitalized assets during the current quarter were ₹64 crores and ₹124 crores during the half year.
The company anticipates CAPEX of approximately ₹1,000 crores including Kakinada for the current year, pushing total CAPEX to around ₹1,600 crores.
Future CAPEX will depend on finalized Custom Synthesis projects and expansion plans, with ongoing investments expected but possibly lower than the current year unless new opportunities arise.
Divi’s is also expanding its Solid Phase Peptide Synthesis facilities and plans to scale up continuous flow chemistry technology to commercial scale in the next 1-2 years.

Track Divi's Lab. — get its next earnings analysis in your feed

How does Divi's Lab. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisDivi's Lab.

Rev 3Mar 3

See where Divi's Lab. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Divi's Lab. rank in Pharmaceuticals & Biotechnology?

Compare Divi's Lab. against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Divi's Lab.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Torrent Pharmaceuticals Ltd vs Laurus Labs Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Divi's Lab. Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Divi's Lab. rank in Pharmaceuticals & Biotechnology?

Continue your research

What Divi's Lab.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season